var data={"title":"Visceral leishmaniasis: Clinical manifestations and diagnosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Visceral leishmaniasis: Clinical manifestations and diagnosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Caryn Bern, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 26, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Visceral leishmaniasis (VL), also known as kala-azar (black fever in Hindi), is a disease primarily caused by <em>Leishmania donovani </em>and <em>L. infantum </em>(synonym <em>L. chagasi</em>) that is transmitted by sandflies (<a href=\"image.htm?imageKey=ID%2F58861\" class=\"graphic graphic_table graphicRef58861 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. Rarely, visceral disease has been reported in patients infected with leishmanial species usually associated with cutaneous disease, in particular, <em>L. mexicana</em> and <em>L. tropica</em> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/2-5\" class=\"abstract_t\">2-5</a>]. The major clinical manifestations caused by <em>L. donovani</em> and <em>L. infantum</em> are not generally distinguishable, and specialized techniques are needed to identify the species. However, treatment decisions for VL usually do not require species identification since they are based on disease severity, geographic origin, and the presence of HIV and other coinfections.</p><p>Issues related to clinical manifestations and diagnosis of visceral leishmaniasis will be reviewed here. Issues related to epidemiology and treatment of VL are discussed separately. (See <a href=\"topic.htm?path=visceral-leishmaniasis-treatment\" class=\"medical medical_review\">&quot;Visceral leishmaniasis: Treatment&quot;</a> and <a href=\"topic.htm?path=visceral-leishmaniasis-epidemiology-and-control\" class=\"medical medical_review\">&quot;Visceral leishmaniasis: Epidemiology and control&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Leishmania</em> invade and replicate within host macrophages, evading innate and cell-mediated immune responses. Infection generally appears to persist after clinical cure of the primary infection [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Evasion and persistence are achieved through a combination of strategies including neutralization of complement components, preventing release of macrophage superoxide and nitric oxide, and suppressing induction of antigen-specific CD4+ T helper lymphocytes [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Spontaneous recovery is rare, although some relatively mild, self-limited cases of visceral leishmaniasis have been reported in a cohort of Brazilian children [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Asymptomatic infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many leishmaniasis infections are asymptomatic, reflecting the ability of the host immune system to control the parasite [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/10,11\" class=\"abstract_t\">10,11</a>]. The ratio of asymptomatic infection to clinically manifest disease varies widely, from &gt;30:1 in Europe to 6:1 in Brazilian children and 4:1 in Bangladesh. This may reflect differences in parasite virulence, human genetic predisposition, nutritional status, and other factors [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/11-18\" class=\"abstract_t\">11-18</a>].</p><p>Subclinical infections can be detected early in their course with serologic testing. The later development of a protective cell-mediated immune response can be detected via leishmanin skin testing (see <a href=\"#H8\" class=\"local\">'Diagnosis'</a> below). The majority of patients with subclinical infection harbor viable parasites lifelong and can develop reactivation disease if immunosuppression occurs, although there does not appear to be a role for primary prophylaxis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/6,19\" class=\"abstract_t\">6,19</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Visceral leishmaniasis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most important clinical manifestation of visceral leishmaniasis (VL) is the syndrome known as kala-azar (Hindi for &quot;black fever&quot;). The incubation period is usually two to six months but can range from a few weeks to several years. Onset of symptoms is usually insidious or subacute, with slow progression of malaise, fever, weight loss, and splenomegaly (with or without hepatomegaly) over a period of months [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. In rare cases, acute febrile illness can occur with rapidly progressive symptoms.</p><p>Patients may complain of abdominal discomfort and fullness that may be localized to the left upper quadrant. The spleen is usually firm and minimally tender, but in some patients palpation is quite painful, presumably due to capsular pressure from rapid enlargement [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/20\" class=\"abstract_t\">20</a>]. Hepatomegaly is usually less marked than splenomegaly. Lymphadenopathy may be observed in East African VL but is rare outside this region.</p><p>Since parasites replicate in the reticuloendothelial system, very high parasite loads accumulate in the spleen, liver, and bone marrow. Severe anemia can occur due to bone marrow suppression, hemolysis, and splenic sequestration. Advanced kala-azar is associated with marked cachexia, hypoalbuminemia, and edema. Late in the course of disease, hepatic dysfunction, jaundice, and ascites can occur. Thrombocytopenia and hepatic dysfunction contribute to hemorrhagic complications. Patients may have spontaneous bleeding from the gingiva, nasal mucosa, or other sites. Rarely, chronic diarrhea and malabsorption can occur as a result of parasitic invasion of the intestine [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Kala-azar (&quot;black fever&quot;) refers to darkening of the skin, which is a common symptom in South Asia but not elsewhere [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/22\" class=\"abstract_t\">22</a>]. This appears to have been more common in classic descriptions of the disease from the early 20th century but has also been reported in more recent case series [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/20\" class=\"abstract_t\">20</a>].</p><p>Immunosuppression increases risk for secondary bacterial infections. Among 30 Brazilian children with kala-azar, 60 percent developed bacterial infections (eg, cutaneous and oral mucosal infections, pneumonia, otitis media, gastrointestinal infections, and sepsis) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"#H2\" class=\"local\">'Pathophysiology'</a> above.)</p><p>Kala-azar during pregnancy can lead to spontaneous abortion or congenital leishmaniasis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/24\" class=\"abstract_t\">24</a>].</p><p>Kala-azar is nearly always lethal without treatment [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/25-27\" class=\"abstract_t\">25-27</a>]. Even with treatment, fatality rates can be 10 percent or higher. Jaundice, wasting, severe anemia, and HIV coinfection are associated with increased mortality [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/28-30\" class=\"abstract_t\">28-30</a>]. The triad of HIV, VL, and tuberculosis is increasingly reported in India and Ethiopia [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/31\" class=\"abstract_t\">31</a>]. Tuberculosis coinfection also increases VL mortality, even in the absence of HIV [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/32,33\" class=\"abstract_t\">32,33</a>]. (See <a href=\"#H19\" class=\"local\">'HIV-VL coinfection'</a> below.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Viscerotropic disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Viscerotropic leishmaniasis is a term used for a systemic illness similar to but substantially milder than kala-azar. The syndrome was described among eight United States military veterans of the 1991 Gulf War and was attributed to <em>L. tropica</em> infection (a species that usually causes cutaneous disease) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Symptoms included fever, malaise, cough, intermittent diarrhea, abdominal pain, adenopathy, and mild hepatosplenomegaly. Treatment with <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">sodium stibogluconate</a> was administered to six patients; the remaining two had spontaneous recovery without antileishmanial treatment.</p><p class=\"headingAnchor\" id=\"H24542225\"><span class=\"h3\">Renal impairment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mild renal impairment appears to occur in a significant proportion of adults and children with visceral leishmaniasis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/34-37\" class=\"abstract_t\">34-37</a>]. Most published data come from areas where VL is due to <em>L. infantum</em>, but a study of children with VL in India suggests that both parasite species affect the kidney [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/38\" class=\"abstract_t\">38</a>].</p><p>One study of 49 adults in Brazil demonstrated abnormal urinalysis (proteinuria, hematuria, <span class=\"nowrap\">and/or</span> white blood cells) in 32 percent, creatinine in 16 percent, elevated blood urea nitrogen in 8 percent, elevated quantitative proteinuria in 57 percent, and creatinine clearance &lt;80 <span class=\"nowrap\">mL/minute/1</span>.7 m<sup>2</sup> in 37 percent of patients [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/35\" class=\"abstract_t\">35</a>]. Of seven patients who underwent renal biopsy, all had interstitial nephritis and three also had glomerulonephritis (considered minimal in two cases). The renal injury was reversible with effective treatment of VL. Within one month of treatment, all patients had normal serum creatinine and blood urea nitrogen concentration; the glomerular filtration rate improved but remained mildly diminished in 32 percent of cases.</p><p>Another study including 146 Brazilian children noted renal impairment in 45 percent of cases [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/36\" class=\"abstract_t\">36</a>]. The estimated glomerular filtration rate was reduced by 25, 50, and 100 percent in 67, 31, and 1 percent of cases, respectively. The risk of renal impairment was increased among younger children and those with secondary bacterial infection. Patients treated with amphotericin had a lower rate of renal impairment compared with those treated with meglumine antimoniate. No patients required dialysis.</p><p>In a study of 40 Indian children between 2 and 14 years old with VL, 10 percent had albuminuria, 20 percent had white blood cells in urine, 10 percent had hematuria, 37 percent had microalbuminuria, and 27 percent had decreased estimated glomerular filtration rate (values of 60 to 89 <span class=\"nowrap\">mL/minute/1</span>.73 m<sup>2</sup>) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/38\" class=\"abstract_t\">38</a>]. Renal injury in VL is generally attributed to immune-complex interstitial nephritis, but animal studies suggest that the etiology may also involve cellular inflammatory responses [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/37,39\" class=\"abstract_t\">37,39</a>]. Based on these data, renal function should be monitored routinely in VL, but the only treatment needed in most cases is effective antileishmanial therapy.</p><p class=\"headingAnchor\" id=\"H4576731\"><span class=\"h3\">Hemophagocytic lymphohistiocytosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hemophagocytic lymphohistiocytosis (HLH) is a systemic disorder of excess immune activation that can be triggered by certain infections; it is an uncommon complication of visceral leishmaniasis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/40,41\" class=\"abstract_t\">40,41</a>]. However, the incidence may be greater in VL-endemic areas than previously thought. As an example, in one series of 127 children with VL severe enough to warrant admission to a tertiary care hospital in Brazil, HLH was observed in 28 percent of cases [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/42\" class=\"abstract_t\">42</a>]. HLH and VL share clinical features including fever, hepatosplenomegaly, and pancytopenia; the diagnostic criteria for HLH are discussed separately. (See <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of hemophagocytic lymphohistiocytosis&quot;</a>.)</p><p>Timely diagnosis is important; while 60 to 70 percent of patients with HLH secondary to VL respond to antileishmanial treatment alone, a delay in diagnosis of HLH may increase the need for adjunctive therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=treatment-and-prognosis-of-hemophagocytic-lymphohistiocytosis\" class=\"medical medical_review\">&quot;Treatment and prognosis of hemophagocytic lymphohistiocytosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nonspecific laboratory findings of VL include anemia, neutropenia, eosinopenia, and thrombocytopenia [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/10\" class=\"abstract_t\">10</a>]. The anemia is normocytic and normochromic, unless iron deficiency is also present. The etiology of anemia is thought to be multifactorial, including bone marrow suppression, hemolysis, and hypersplenism [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/43\" class=\"abstract_t\">43</a>]. An elevated neutrophil count is uncharacteristic of VL and should prompt a search for secondary bacterial infection. Elevated liver enzymes and bilirubin are also seen. Hypergammaglobulinemia results from polyclonal B cell activation. Severe anemia and frank jaundice are associated with a poor prognosis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/28,32,44\" class=\"abstract_t\">28,32,44</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H1543162716\"><span class=\"h2\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diagnostic methods to establish the diagnosis of visceral leishmaniasis (VL) include visualization of the characteristic amastigote in smears or tissue (histopathology), parasite isolation by in vitro culture, molecular detection of parasite DNA, and serologic testing [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. It is reasonable to pursue multiple diagnostic approaches to maximize the likelihood of a positive result in conjunction with the expertise of a reference laboratory. Serologic testing is warranted for patients with suspected VL who have negative or inconclusive results for histopathology, culture, and molecular testing [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Definitive diagnosis of VL requires the demonstration of parasite by smear or culture in tissue (usually bone marrow or spleen). The utility of less invasive diagnostic tools (such as demonstration of specific antibodies, antigens, or parasite DNA in peripheral blood specimens) depends on the clinical status of the patient, the geographic origin of the parasite, the methods employed, and laboratory experience [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/45\" class=\"abstract_t\">45</a>]. In patients with HIV infection, the sensitivity of serologic tests is diminished; in these patients, parasite loads are very high, raising the sensitivity of culture and molecular assays in peripheral blood [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1,46,47\" class=\"abstract_t\">1,46,47</a>].</p><p>An expert review recommends against routine diagnostic testing for asymptomatic leishmanial infection, including in those who may undergo immunosuppressive therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Clinical and laboratory consultation for VL diagnosis, including access to serologic and molecular testing, culture medium, and slide review, are available by contacting the United States Centers for Disease Control and Prevention (CDC) Parasitic Diseases Public Inquiries line (404-718-4745; email parasites@cdc.gov) or, for emergencies outside business hours, the CDC Emergency Operations Center (770-488-7100). Diagnostic information, an image library, and consultations are also available through the <a href=\"http://www.dpd.cdc.gov/&amp;token=YSj8hO8d8jZxXImOk3DaSdTVbvElmM120zXcR2iEz1Q=&amp;TOPIC_ID=5732\" target=\"_blank\" class=\"external\">CDC DPDx website</a>. The Walter Reed Army Institute of Research also provides leishmaniasis diagnostic services for military and Department of Defense civilian personnel through its <a href=\"http://www.wrair.army.mil/OtherServices_LDL.aspx&amp;token=5Ut0WhZCN/6asDNCr8n3GlokdoZ+YbIKgPwNKJprLy5w5ai/j/VZ8LJ7HFgKEurjzNt2Y59KINlVU6NZMmaY9A==&amp;TOPIC_ID=5732\" target=\"_blank\" class=\"external\">Leishmania Diagnostic Laboratory</a>.</p><p class=\"headingAnchor\" id=\"H1152948679\"><span class=\"h2\">Specimen collection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bone marrow aspiration (for histopathology, culture, and molecular testing) is the preferred diagnostic specimen. Other potential tissue specimens (for histopathology, culture, and molecular testing) include spleen, enlarged lymph nodes, and whole blood (buffy coat). Serum should be collected for detection of antileishmanial antibodies for patients with suspected VL who have negative or inconclusive results for histopathology, culture, and molecular testing [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>].</p><p>In immunocompromised individuals, blood is a useful diagnostic specimen for buffy coat histopathology examination, culture, and molecular testing.</p><p class=\"headingAnchor\" id=\"H2693328787\"><span class=\"h2\">Diagnostic tools</span></p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histopathologic demonstration of parasite requires needle aspiration or biopsy of affected organs [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. Usually, bone marrow or spleen aspirations are performed (sensitivity 70 and 96 percent in one comparative analysis); in Sudanese VL, lymph node aspiration can also be performed, although sensitivity is lower than at the other sites (sensitivity 58 percent) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/48\" class=\"abstract_t\">48</a>].</p><p>Splenic aspiration is associated with risk of splenic hemorrhage or bowel perforation. These risks are reported to be low in experienced hands, but the complications can be lethal [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/45,49,50\" class=\"abstract_t\">45,49,50</a>]. Splenic aspiration should be performed only if the platelet count and prothrombin times are adequate.</p><p>Bone marrow aspirates are generally safer than splenic aspirates and in one study the sensitivity of bone marrow examination was found to be proportional to the amount of time spent examining the smear (66 and 92 percent at five minutes and one hour, respectively) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/49\" class=\"abstract_t\">49</a>].</p><p>Aspirated material should be inoculated into culture and used to prepare a Giemsa-stained smear [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/51\" class=\"abstract_t\">51</a>]. Biopsy specimens should be prepared with tissue sections as well as touch preparation, which facilitates visualization of intracellular amastigotes in a cell monolayer [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/45\" class=\"abstract_t\">45</a>].</p><p>Histopathologic diagnosis requires visualization of amastigotes; these are spherical or ovoid bodies that measure 1 to 5 microns long by 1 to 2 microns wide. Amastigotes are usually found within macrophages but may be seen outside of cells, especially in touch preparations. Amastigotes possess a large nucleus and a prominent deeply stained rod-like organelle called the kinetoplast, made up of tightly concatenated extranuclear DNA. The presence of the kinetoplast is the characteristic that most clearly distinguishes <em>Leishmania</em> amastigotes from <em>Histoplasma</em>, whose size is similar. The parasite load can be quantified based on a scale from 0 (no parasites in 1000 microscopic fields) to 6+ (&gt;100 parasites per microscopic field) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/51\" class=\"abstract_t\">51</a>]. Because the number of parasites can vary widely from field to field, quantification requires careful, prolonged examination of the slide (<a href=\"image.htm?imageKey=ID%2F52344\" class=\"graphic graphic_picture graphicRef52344 \">picture 1</a>).</p><p class=\"headingAnchor\" id=\"H2396772608\"><span class=\"h3\">Culture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Culture can be performed in Novy-McNeal-Nicolle or other parasitic growth media (available upon request from the CDC) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/45\" class=\"abstract_t\">45</a>]. Two to three drops of buffy coat, bone marrow, or splenic aspirate are inoculated into the medium. The culture is checked weekly by microscopy for the presence of promastigotes for up to four weeks after inoculation [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/52,53\" class=\"abstract_t\">52,53</a>]. Growth usually occurs within two weeks but may take longer using material with few parasites. An adaptation using microtiter plates has been successfully applied in India [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/54\" class=\"abstract_t\">54</a>]. The sensitivity of culture depends on the parasite load in the sampled material but is generally 60 to 85 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/52-54\" class=\"abstract_t\">52-54</a>]. </p><p class=\"headingAnchor\" id=\"H2524200777\"><span class=\"h3\">Molecular techniques</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polymerase chain reaction (PCR) has been used for diagnosis of VL; many different primer sets, protocols, and visualization methods have been evaluated [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/55-59\" class=\"abstract_t\">55-59</a>]. PCR sensitivity is higher than for smear or culture but is variable depending on the tissue used [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/60,61\" class=\"abstract_t\">60,61</a>]. Sensitivity is highest in tissues (eg, spleen or bone marrow); it is more variable in peripheral blood, likely because the circulating parasite load varies with the severity of disease.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Serologic tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In areas with access to advanced laboratory techniques, serologic testing is used primarily for patients with suspected VL who have negative or inconclusive results for histopathology, culture, and molecular testing [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1\" class=\"abstract_t\">1</a>]. In endemic regions with limited laboratory access, serological tests are used as the primary test to confirm the diagnosis in patients with high clinical suspicion of VL [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/62\" class=\"abstract_t\">62</a>]. Indirect fluorescent antibody tests (IFA) and enzyme-linked immunosorbent assays (ELISAs) are useful diagnostic tools since visceral leishmaniasis infection stimulates intense polyclonal B cell activation, leading to production of a broad array of antibodies [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/63\" class=\"abstract_t\">63</a>].</p><p>The direct agglutination test (DAT) is a diagnostic tool that can be read by eye and therefore requires less equipment than ELISA so can be useful in developing settings [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/64\" class=\"abstract_t\">64</a>]. The sensitivity and specificity of serologic assays vary depending on the antigen and format used [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/45,65\" class=\"abstract_t\">45,65</a>]. In general, the assays that use whole parasite antigens have high sensitivity but relatively low specificity because of cross-reaction with Chagas disease, malaria, and other infections (as well as nonspecific cross-reactivity) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/65\" class=\"abstract_t\">65</a>].</p><p>The recombinant kinesin antigen (rK39) is a useful antigen in ELISA assays with high sensitivity and specificity in immunocompetent patients in the Indian subcontinent (92.8 to 100 percent and 96 to 100 percent, respectively) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/66-68\" class=\"abstract_t\">66-68</a>]. The sensitivity is lower and more variable in East Africa and Brazil (61.5 to 91 percent), although specificity remains high (&gt;95 percent in Brazil, 90.8 to 98 percent in Africa) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/69-71\" class=\"abstract_t\">69-71</a>]. This antigen has also been adapted for use in immunochromatographic strip format as a rapid test that requires minimal equipment and is easy to use in developing settings [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/45,69,72,73\" class=\"abstract_t\">45,69,72,73</a>]. The accuracy of the rK39 tests is comparable to the direct agglutination test.</p><p>In regions where VL is endemic, positive antibody test results may be observed among asymptomatic individuals with subclinical infection [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/12,72\" class=\"abstract_t\">12,72</a>]. Patients with clinical recovery after successful treatment of VL continue to have positive serology for months to years, so these assays cannot be used to assess response to treatment [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/1,12,74\" class=\"abstract_t\">1,12,74</a>]. For these reasons, a positive serological test is not definitive proof of active VL; such results must be interpreted in the context of clinical and epidemiologic information. Serum antibodies may be low or undetectable in immunocompromised individuals.</p><p>Prior to the development of the assays described above, one early diagnostic tool was the formol-gel (aldehyde) test; placing a drop of formaldehyde in the serum from a patient with VL would cause the specimen to form a gel. However, this finding is observed only when the disease is quite advanced. In Nepal and Uganda, the sensitivity was noted to be 40 to 66 percent; specificity was also low [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/75,76\" class=\"abstract_t\">75,76</a>]. This test was widely used from the 1920s until more specific immunologic testing became available in the 1980s.</p><p class=\"headingAnchor\" id=\"H4188301534\"><span class=\"h3\">Other assays</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Assays that do not play an important role in diagnosis of VL include the leishmanin skin test and the urine leishmanial antigen assays.</p><p>The leishmanin skin test (also called the Montenegro skin test) is almost uniformly negative in active VL and has no role in VL diagnosis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/77\" class=\"abstract_t\">77</a>]. The test is a valuable tool for assessing the degree of exposure and immunity in a population; a positive response usually develops 2 to 24 months after clinical recovery [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/77-80\" class=\"abstract_t\">77-80</a>]. Recovered immunocompetent patients usually have strong leishmanin skin test responses; HIV coinfection is associated with anergy to <em>Leishmania</em> antigens.</p><p>The most frequently used urine leishmanial antigen assay is the kala-azar latex agglutination test (KAtex). KAtex has high specificity but sensitivity is &lt;70 percent, limiting its diagnostic utility [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/81-83\" class=\"abstract_t\">81-83</a>]. This assay becomes negative rapidly after successful treatment.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SPECIAL CIRCUMSTANCES</span></p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Post-kala-azar dermal leishmaniasis</span></p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Post-kala-azar dermal leishmaniasis (PKDL) is a chronic skin rash observed following clinical response to treatment for visceral leishmaniasis due to <em>L. donovani</em> [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/84,85\" class=\"abstract_t\">84,85</a>]. PKDL usually presents with erythematous or hypopigmented macules that sometimes progress to plaques or nodules (<a href=\"image.htm?imageKey=ID%2F80619\" class=\"graphic graphic_picture graphicRef80619 \">picture 2</a> and <a href=\"image.htm?imageKey=ID%2F75252\" class=\"graphic graphic_picture graphicRef75252 \">picture 3</a> and <a href=\"image.htm?imageKey=ID%2F58427\" class=\"graphic graphic_picture graphicRef58427 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/84\" class=\"abstract_t\">84</a>]. The lesions resemble (and must be differentiated from) those of leprosy but are not associated with sensorineural changes [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/86\" class=\"abstract_t\">86</a>]. Risk factors for progression to PKDL are uncertain but may include immune response to infection, parasite strain, and efficacy of therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/85,87,88\" class=\"abstract_t\">85,87,88</a>].</p><p>PKDL has been described among patients in the Horn of Africa and in South Asia. In Sudan, about 50 to 60 percent of patients with VL develop PKDL within six months of treatment; most cases are mild and resolve without further therapy [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/84\" class=\"abstract_t\">84</a>]. In South Asia, the incidence of PKDL after VL is about 5 to 15 percent, with an average interval of about two years [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/85,89,90\" class=\"abstract_t\">85,89,90</a>].</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>PKDL is diagnosed by microscopy (skin biopsies or slit skin specimens), culture, <span class=\"nowrap\">and/or</span> molecular methods [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/91,92\" class=\"abstract_t\">91,92</a>]. In macular lesions, parasites are sparse and may be difficult to detect in smears or histology. Serological tests are often positive in PKDL patients although it is uncertain whether positive serology is an indicator of PKDL or a persistent antibody response to the antecedent infection, since serum antibodies can persist for years after treatment [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/91,92\" class=\"abstract_t\">91,92</a>]. (See <a href=\"#H11\" class=\"local\">'Serologic tests'</a> above.)</p><p>The treatment of PKDL is discussed separately. (See <a href=\"topic.htm?path=visceral-leishmaniasis-treatment#H15\" class=\"medical medical_review\">&quot;Visceral leishmaniasis: Treatment&quot;, section on 'Post kala-azar dermal leishmaniasis'</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">HIV-VL coinfection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Human immunodeficiency virus (HIV) coinfection of VL has been identified as an emerging challenge for VL control [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/46\" class=\"abstract_t\">46</a>]. HIV infection increases the risk of VL and, conversely, VL accelerates HIV disease progression. The problem is severe in parts of eastern Africa, particularly Ethiopia, where the prevalence of HIV infection in VL patients was reported to be as high as 40 percent in earlier studies and 18 percent in subsequent publication [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/47\" class=\"abstract_t\">47</a>]. In Brazil in 2011, the ministry of health noted a coinfection rate of 6 percent of VL cases. Another study among 2077 patients with VL in Bihar, India, noted 2.4 percent with newly diagnosed HIV infection [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/93\" class=\"abstract_t\">93</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, patients with HIV-VL coinfection present with the manifestations described in the preceding section. Splenomegaly was observed less frequently observed in the setting of HIV-coinfection (80 versus 97 percent in one series) [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/94\" class=\"abstract_t\">94</a>]. (See <a href=\"#H5\" class=\"local\">'Visceral leishmaniasis'</a> above.)</p><p>Among patients with profound immunosuppression (eg, CD4 &lt;50), parasitic infection of atypical sites may occur, including the gastrointestinal tract, peritoneal space, lung, pleural space, and skin [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/94-97\" class=\"abstract_t\">94-97</a>]. Esophageal involvement can lead to dysphagia and odynophagia, which must be distinguished from other causes of esophagitis such as candidiasis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/95\" class=\"abstract_t\">95</a>]. Mucocutaneous manifestations include nonulcerative cutaneous lesions that may mimic Kaposi's sarcoma, nodular diffuse leishmaniasis, mucosal lesions, and PKDL [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/97-100\" class=\"abstract_t\">97-100</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV-VL coinfected patients tend to have relatively low antibody titers [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/95,101\" class=\"abstract_t\">95,101</a>]. In one study, the sensitivity of various serological tests ranged from 25 to 50 percent [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/102\" class=\"abstract_t\">102</a>]. Therefore, histopathologic or molecular confirmation is warranted for definitive diagnosis [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/101\" class=\"abstract_t\">101</a>]. (See <a href=\"#H9\" class=\"local\">'Histopathology'</a> above.)</p><p>In contrast to serologic tests, molecular techniques tend to have high sensitivity in HIV-VL coinfected patients, since in these individuals the parasite load in peripheral blood specimens is generally high [<a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/55\" class=\"abstract_t\">55</a>]. The parasite load tends to be inversely proportional to the CD4 count; in patients with very low CD4 counts, polymerase chain reaction (PCR) and hemoculture have high sensitivity, and amastigotes may be visualized in buffy coat smears. (See <a href=\"#H2524200777\" class=\"local\">'Molecular techniques'</a> above.)</p><p>The treatment of HIV-VL coinfection is discussed separately. (See <a href=\"topic.htm?path=visceral-leishmaniasis-treatment#H13\" class=\"medical medical_review\">&quot;Visceral leishmaniasis: Treatment&quot;, section on 'HIV coinfection'</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of visceral leishmaniasis includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malaria &ndash; Both malaria and visceral leishmaniasis may present with fever, malaise, and splenomegaly; symptoms of malaria generally occur acutely whereas symptoms of visceral leishmaniasis tend to be chronic. Tropical splenomegaly can also occur in the setting of chronic malaria. The diagnosis of malaria is established by blood smear or rapid diagnostic testing. (See <a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">&quot;Clinical manifestations of malaria in nonpregnant adults and children&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">&quot;Diagnosis of malaria&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histoplasmosis &ndash; Patients with acute histoplasmosis present with fever, fatigue, hepatosplenomegaly, and pancytopenia; these manifestations usually occur in the setting of immunosuppression. The diagnosis may be established by antigen testing, culture, or histopathology. (See <a href=\"topic.htm?path=pathogenesis-and-clinical-manifestations-of-disseminated-histoplasmosis\" class=\"medical medical_review\">&quot;Pathogenesis and clinical manifestations of disseminated histoplasmosis&quot;</a> and <a href=\"topic.htm?path=diagnosis-and-treatment-of-disseminated-histoplasmosis-in-hiv-uninfected-patients\" class=\"medical medical_review\">&quot;Diagnosis and treatment of disseminated histoplasmosis in HIV-uninfected patients&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Amebic liver abscess &ndash; Patients with amebic liver abscess usually present with one to two weeks of right upper quadrant pain and fever; other symptoms may include sweating, malaise, weight loss, and anorexia. The diagnosis is established by radiographic imaging. (See <a href=\"topic.htm?path=extraintestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">&quot;Extraintestinal Entamoeba histolytica amebiasis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Schistosomiasis &ndash; Hepatosplenic schistosomiasis consists of granulomatous inflammation and subsequent fibrosis of the periportal spaces of the liver, with subsequent portal hypertension and splenomegaly. The diagnosis is established by visualization of eggs on microscopy <span class=\"nowrap\">and/or</span> serology. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-schistosomiasis\" class=\"medical medical_review\">&quot;Diagnosis of schistosomiasis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphoma &ndash; Lymphoma may present with lymphadenopathy, hepatomegaly, splenomegaly, cytopenia, fever, night sweats, and weight loss. The diagnosis is established by histopathology. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of non-Hodgkin lymphoma&quot;</a> and <a href=\"topic.htm?path=epidemiology-pathologic-features-and-diagnosis-of-classical-hodgkin-lymphoma\" class=\"medical medical_review\">&quot;Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tuberculosis &ndash; Extrapulmonary tuberculosis may present with seeding of nearly any organ of the body, including hepatic <span class=\"nowrap\">and/or</span> splenic disease. The diagnosis is established by culture of acid-fast bacilli from the sputum or other <span class=\"nowrap\">fluid/tissue</span>. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-miliary-tuberculosis\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of miliary tuberculosis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Visceral leishmaniasis (VL) is primarily caused by <em>L. donovani</em> and <em>L. infantum</em> (synonym <em>L. chagasi</em>). <em>Leishmania</em> invade and replicate within host macrophages, evading innate and cell-mediated immune responses. Infection generally appears to persist after clinical cure of the primary infection. (See <a href=\"#H2\" class=\"local\">'Pathophysiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Many leishmanial infections are asymptomatic, reflecting the ability of the host immune system to control the parasite. The ratio of asymptomatic infection to clinical infection varies widely and may depend on a variety of factors. Most patients with subclinical infection harbor viable parasites lifelong and can develop reactivation disease if immunosuppression occurs. (See <a href=\"#H4\" class=\"local\">'Asymptomatic infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most important clinical manifestation of VL is the syndrome known as kala-azar (Hindi for &quot;black fever&quot;). The incubation period is usually two to six months but can range from a few weeks to several years. Onset of symptoms is usually insidious or subacute, with slow progression of malaise, fever, weight loss, and splenomegaly (with or without hepatomegaly) over a period of months. Less frequently, acute febrile illness can occur with rapidly progressive symptoms. (See <a href=\"#H5\" class=\"local\">'Visceral leishmaniasis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Definitive diagnosis requires demonstration of the parasite by either histopathology or culture of material obtained by needle aspiration or biopsy from affected organs (usually bone marrow or spleen). Aspirated material should be inoculated into culture and the remainder used to prepare a Giemsa-stained smear. Biopsy specimens should be prepared with tissue sections as well as touch preparation. Histopathologic diagnosis requires visualization of amastigotes; culture can be performed in Novy-McNeal-Nicolle or other parasitic growth media. Molecular methods (ie, polymerase chain reaction) can also be used to detect parasite in tissue or peripheral blood. (See <a href=\"#H9\" class=\"local\">'Histopathology'</a> above and <a href=\"#H2396772608\" class=\"local\">'Culture'</a> above and <a href=\"#H2524200777\" class=\"local\">'Molecular techniques'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serologic tests including indirect fluorescent antibody tests (IFA) and enzyme-linked immunosorbent assays (ELISAs) are useful diagnostic tools. The direct agglutination test (DAT) requires less equipment than ELISA so is useful in developing settings. The recombinant kinesin antigen (rK39) is a useful antigen in ELISA assays as well as in immunochromatographic strip format as a rapid test. A positive serological test is not definitive proof of active VL; such results must be interpreted in the context of clinical and epidemiological information. (See <a href=\"#H11\" class=\"local\">'Serologic tests'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Post-kala-azar dermal leishmaniasis (PKDL) is a chronic skin rash typically observed following clinical response to treatment for visceral leishmaniasis. PKDL occurs in up to 60 percent of VL patients in East Africa and in 5 to 15 percent of VL patients in the Indian subcontinent. PKDL is rare in areas with <em>L. infantum</em> VL. It usually presents with erythematous or hypopigmented macules, which sometimes progress to plaques or nodules. The diagnosis is made by evaluation of skin biopsies or slit skin specimens by microscopy, culture, <span class=\"nowrap\">and/or</span> molecular methods. (See <a href=\"#H16\" class=\"local\">'Post-kala-azar dermal leishmaniasis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with HIV-VL coinfection may have a lower incidence of splenomegaly. Among patients with profound immunosuppression parasitic infection of atypical sites may occur, including the gastrointestinal tract, peritoneal space, lung, pleural space, and skin. HIV-VL coinfected patients tend to have relatively low antibody titers but molecular techniques have good sensitivity given generally high levels of parasitemia in peripheral blood specimens. Histopathologic or molecular confirmation is warranted for definitive diagnosis. (See <a href=\"#H19\" class=\"local\">'HIV-VL coinfection'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH) (2016). http://cid.oxfordjournals.org/content/early/2016/11/03/cid.ciw670.full.pdf+html (Accessed on November 16, 2016).</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/2\" class=\"nounderline abstract_t\">Barral A, Badar&oacute; R, Barral-Netto M, et al. Isolation of Leishmania mexicana amazonensis from the bone marrow in a case of American visceral leishmaniasis. Am J Trop Med Hyg 1986; 35:732.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/3\" class=\"nounderline abstract_t\">Monroy-Ostria A, Hernandez-Montes O, Barker DC. Aetiology of visceral leishmaniasis in Mexico. Acta Trop 2000; 75:155.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/4\" class=\"nounderline abstract_t\">Sacks DL, Kenney RT, Kreutzer RD, et al. Indian kala-azar caused by Leishmania tropica. Lancet 1995; 345:959.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/5\" class=\"nounderline abstract_t\">Magill AJ, Gr&ouml;gl M, Gasser RA Jr, et al. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328:1383.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/6\" class=\"nounderline abstract_t\">Bogdan C. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol 2008; 10:1221.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/7\" class=\"nounderline abstract_t\">Bogdan C, R&ouml;llinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int J Parasitol 1998; 28:121.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/8\" class=\"nounderline abstract_t\">Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 1989; 83:1253.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/9\" class=\"nounderline abstract_t\">Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986; 154:1003.</a></li><li class=\"breakAll\">Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.696.</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/11\" class=\"nounderline abstract_t\">Singh OP, Hasker E, Sacks D, et al. Asymptomatic Leishmania infection: a new challenge for Leishmania control. Clin Infect Dis 2014; 58:1424.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/12\" class=\"nounderline abstract_t\">Bern C, Haque R, Chowdhury R, et al. The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village. Am J Trop Med Hyg 2007; 76:909.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/13\" class=\"nounderline abstract_t\">Badar&oacute; R, Jones TC, Loren&ccedil;o R, et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis 1986; 154:639.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/14\" class=\"nounderline abstract_t\">Moral L, Rubio EM, Moya M. A leishmanin skin test survey in the human population of l'Alacant&iacute; region (Spain): implications for the epidemiology of Leishmania infantum infection in southern Europe. Trans R Soc Trop Med Hyg 2002; 96:129.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/15\" class=\"nounderline abstract_t\">Anstead GM, Chandrasekar B, Zhao W, et al. Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection. Infect Immun 2001; 69:4709.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/16\" class=\"nounderline abstract_t\">Blackwell JM, Fakiola M, Ibrahim ME, et al. Genetics and visceral leishmaniasis: of mice and man. Parasite Immunol 2009; 31:254.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/17\" class=\"nounderline abstract_t\">Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis 1987; 156:1030.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/18\" class=\"nounderline abstract_t\">Karplus TM, Jeronimo SM, Chang H, et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002; 70:6919.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/19\" class=\"nounderline abstract_t\">de Rossell RA, de Duran RJ, Rossell O, Rodr&iacute;guez AM. Is leishmaniasis ever cured? Trans R Soc Trop Med Hyg 1992; 86:251.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/20\" class=\"nounderline abstract_t\">Bern C, Joshi AB, Jha SN, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 2000; 63:184.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/21\" class=\"nounderline abstract_t\">Baba CS, Makharia GK, Mathur P, et al. Chronic diarrhea and malabsorption caused by Leishmania donovani. Indian J Gastroenterol 2006; 25:309.</a></li><li class=\"breakAll\">Magill AJ. Visceral leishmaniasis (kala-azar). In: Hunter's Tropical Medicine and Emerging Infectious Diseases, 8th ed, Strickland GT (Ed), W.B.Saunders Company, Philadelphia 2000. p.670.</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/23\" class=\"nounderline abstract_t\">Andrade TM, Carvalho EM, Rocha H. Bacterial infections in patients with visceral leishmaniasis. J Infect Dis 1990; 162:1354.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/24\" class=\"nounderline abstract_t\">Pagliano P, Carannante N, Rossi M, et al. Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. J Antimicrob Chemother 2005; 55:229.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/25\" class=\"nounderline abstract_t\">Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996; 14:417.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/26\" class=\"nounderline abstract_t\">Sen Gupta PC. History of kala-azar in India. Indian Medical Gazette 1947; 82:281.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/27\" class=\"nounderline abstract_t\">Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996; 25:862.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/28\" class=\"nounderline abstract_t\">Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004; 38:612.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/29\" class=\"nounderline abstract_t\">Bern C, Hightower AW, Chowdhury R, et al. Risk factors for kala-azar in Bangladesh. Emerg Infect Dis 2005; 11:655.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/30\" class=\"nounderline abstract_t\">Rey LC, Martins CV, Ribeiro HB, Lima AA. American visceral leishmaniasis (kala-azar) in hospitalized children from an endemic area. J Pediatr (Rio J) 2005; 81:73.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/31\" class=\"nounderline abstract_t\">Pandey K, Sinha PK, Ravidas VN, et al. Nexus of infection with human immunodeficiency virus, pulmonary tuberculosis and visceral leishmaniasis: a case report from Bihar, India. Am J Trop Med Hyg 2005; 72:30.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/32\" class=\"nounderline abstract_t\">Herrero M, Orfanos G, Argaw D, et al. Natural history of a visceral leishmaniasis outbreak in highland Ethiopia. Am J Trop Med Hyg 2009; 81:373.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/33\" class=\"nounderline abstract_t\">Mueller Y, Mbulamberi DB, Odermatt P, et al. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health 2009; 14:910.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/34\" class=\"nounderline abstract_t\">Duarte MI, Silva MR, Goto H, et al. Interstitial nephritis in human kala-azar. Trans R Soc Trop Med Hyg 1983; 77:531.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/35\" class=\"nounderline abstract_t\">Dutra M, Martinelli R, de Carvalho EM, et al. Renal involvement in visceral leishmaniasis. Am J Kidney Dis 1985; 6:22.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/36\" class=\"nounderline abstract_t\">Lib&oacute;rio AB, Rocha NA, Oliveira MJ, et al. Acute kidney injury in children with visceral leishmaniasis. Pediatr Infect Dis J 2012; 31:451.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/37\" class=\"nounderline abstract_t\">Lima Verde FA, Lima Verde FA, Lima Verde IA, et al. Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil. J Nephrol 2007; 20:430.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/38\" class=\"nounderline abstract_t\">Verma N, Lal CS, Rabidas V, et al. Microalbuminuria and glomerular filtration rate in paediatric visceral leishmaniasis. Biomed Res Int 2013; 2013:498918.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/39\" class=\"nounderline abstract_t\">Costa FA, Guerra JL, Silva SM, et al. CD4(+) T cells participate in the nephropathy of canine visceral leishmaniasis. Braz J Med Biol Res 2000; 33:1455.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/40\" class=\"nounderline abstract_t\">Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol 2013; 139:713.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/41\" class=\"nounderline abstract_t\">Rajagopala S, Dutta U, Chandra KS, et al. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis--case report and systematic review. J Infect 2008; 56:381.</a></li><li class=\"breakAll\">http://journals.lww.com/pidj/Abstract/2015/12000/Hemophagocytic_Syndrome_in_Children_With_Visceral.7.aspx (Accessed on December 08, 2015).</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/43\" class=\"nounderline abstract_t\">Kager PA, Rees PH. Haematological investigations in visceral leishmaniasis. Trop Geogr Med 1986; 38:371.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/44\" class=\"nounderline abstract_t\">Werneck GL, Batista MS, Gomes JR, et al. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection 2003; 31:174.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/45\" class=\"nounderline abstract_t\">Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002; 9:951.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/46\" class=\"nounderline abstract_t\">Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21:334.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/47\" class=\"nounderline abstract_t\">van Griensven J, Zijlstra EE, Hailu A. Visceral leishmaniasis and HIV coinfection: time for concerted action. PLoS Negl Trop Dis 2014; 8:e3023.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/48\" class=\"nounderline abstract_t\">Zijlstra EE, Ali MS, el-Hassan AM, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg 1992; 86:505.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/49\" class=\"nounderline abstract_t\">da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am J Trop Med Hyg 2005; 72:811.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/50\" class=\"nounderline abstract_t\">Lightner LK, Chulay JD, Bryceson AD. Comparison of microscopy and culture in the detection of Leishmania donovani from splenic aspirates. Am J Trop Med Hyg 1983; 32:296.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/51\" class=\"nounderline abstract_t\">Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32:475.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/52\" class=\"nounderline abstract_t\">Gatti S, Gramegna M, Klersy C, et al. Diagnosis of visceral leishmaniasis: the sensitivities and specificities of traditional methods and a nested PCR assay. Ann Trop Med Parasitol 2004; 98:667.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/53\" class=\"nounderline abstract_t\">L&oacute;pez-V&eacute;lez R, Laguna F, Alvar J, et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol 1995; 33:937.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/54\" class=\"nounderline abstract_t\">Hide M, Singh R, Kumar B, et al. A microculture technique for isolating live Leishmania parasites from peripheral blood of visceral leishmaniasis patients. Acta Trop 2007; 102:197.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/55\" class=\"nounderline abstract_t\">Cruz I, Ca&ntilde;avate C, Rubio JM, et al. A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 2002; 96 Suppl 1:S185.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/56\" class=\"nounderline abstract_t\">le Fichoux Y, Quaranta JF, Aufeuvre JP, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 1999; 37:1953.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/57\" class=\"nounderline abstract_t\">Osman OF, Oskam L, Zijlstra EE, et al. Evaluation of PCR for diagnosis of visceral leishmaniasis. J Clin Microbiol 1997; 35:2454.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/58\" class=\"nounderline abstract_t\">Salotra P, Sreenivas G, Pogue GP, et al. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol 2001; 39:849.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/59\" class=\"nounderline abstract_t\">Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol 2007; 45:21.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/60\" class=\"nounderline abstract_t\">Cruz I, Chicharro C, Nieto J, et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J Clin Microbiol 2006; 44:2343.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/61\" class=\"nounderline abstract_t\">Antinori S, Calattini S, Longhi E, et al. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis 2007; 44:1602.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/62\" class=\"nounderline abstract_t\">World Health Organization. Control of the leishmaniases. World Health Organ Tech Rep Ser 2010; :xii.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/63\" class=\"nounderline abstract_t\">Galv&atilde;o-Castro B, S&aacute; Ferreira JA, Marzochi KF, et al. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis. Clin Exp Immunol 1984; 56:58.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/64\" class=\"nounderline abstract_t\">el Harith A, Kolk AH, Leeuwenburg J, et al. Improvement of a direct agglutination test for field studies of visceral leishmaniasis. J Clin Microbiol 1988; 26:1321.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/65\" class=\"nounderline abstract_t\">Reed SG, Shreffler WG, Burns JM Jr, et al. An improved serodiagnostic procedure for visceral leishmaniasis. Am J Trop Med Hyg 1990; 43:632.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/66\" class=\"nounderline abstract_t\">Badar&oacute; R, Benson D, Eul&aacute;lio MC, et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996; 173:758.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/67\" class=\"nounderline abstract_t\">Badar&oacute; R, Reed SG, Barral A, et al. Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses. Am J Trop Med Hyg 1986; 35:72.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/68\" class=\"nounderline abstract_t\">Qu JQ, Zhong L, Masoom-Yasinzai M, et al. Serodiagnosis of Asian leishmaniasis with a recombinant antigen from the repetitive domain of a Leishmania kinesin. Trans R Soc Trop Med Hyg 1994; 88:543.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/69\" class=\"nounderline abstract_t\">Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 2006; 333:723.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/70\" class=\"nounderline abstract_t\">Cunningham J, Hasker E, Das P, et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis 2012; 55:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/71\" class=\"nounderline abstract_t\">Boelaert M, Verdonck K, Menten J, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev 2014; :CD009135.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/72\" class=\"nounderline abstract_t\">Sundar S, Maurya R, Singh RK, et al. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol 2006; 44:251.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/73\" class=\"nounderline abstract_t\">Sundar S, Reed SG, Singh VP, et al. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 1998; 351:563.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/74\" class=\"nounderline abstract_t\">Houghton RL, Petrescu M, Benson DR, et al. A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy. J Infect Dis 1998; 177:1339.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/75\" class=\"nounderline abstract_t\">Chappuis F, Rijal S, Jha UK, et al. Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal. Trop Med Int Health 2006; 11:31.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/76\" class=\"nounderline abstract_t\">Chappuis F, Mueller Y, Nguimfack A, et al. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol 2005; 43:5973.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/77\" class=\"nounderline abstract_t\">Bern C, Amann J, Haque R, et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh. Am J Trop Med Hyg 2006; 75:744.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/78\" class=\"nounderline abstract_t\">MANSON-BAHR PE. Immunity in kala-azar. Trans R Soc Trop Med Hyg 1961; 55:550.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/79\" class=\"nounderline abstract_t\">Zijlstra EE, el-Hassan AM. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar. Trans R Soc Trop Med Hyg 1993; 87:425.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/80\" class=\"nounderline abstract_t\">Neogy AB, Nandy A, Dastidar BG, Chowdhury AB. Leishmanin test in Indian kala-azar. Trans R Soc Trop Med Hyg 1986; 80:454.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/81\" class=\"nounderline abstract_t\">Boelaert M, El-Safi S, Hailu A, et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 2008; 102:32.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/82\" class=\"nounderline abstract_t\">Sundar S, Agrawal S, Pai K, et al. Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. Am J Trop Med Hyg 2005; 73:269.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/83\" class=\"nounderline abstract_t\">Sundar S, Singh RK, Bimal SK, et al. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III diagnostic accuracy study. Trop Med Int Health 2007; 12:284.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/84\" class=\"nounderline abstract_t\">Zijlstra EE, Musa AM, Khalil EA, et al. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3:87.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/85\" class=\"nounderline abstract_t\">Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol 1995; 34:85.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/86\" class=\"nounderline abstract_t\">Ramesh V. On the differences between post-kala-azar dermal leishmaniasis and leprosy. Trop Doct 1994; 24:120.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/87\" class=\"nounderline abstract_t\">Ansari NA, Ramesh V, Salotra P. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J Infect Dis 2006; 194:958.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/88\" class=\"nounderline abstract_t\">Sreenivas G, Raju BV, Singh R, et al. DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal Leishmaniasis in humans. J Clin Microbiol 2004; 42:1739.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/89\" class=\"nounderline abstract_t\">Rahman KM, Islam S, Rahman MW, et al. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh. Clin Infect Dis 2010; 50:73.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/90\" class=\"nounderline abstract_t\">Zijlstra EE, Alves F, Rijal S, et al. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme. PLoS Negl Trop Dis 2017; 11:e0005877.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/91\" class=\"nounderline abstract_t\">Salotra P, Singh R. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J Med Res 2006; 123:295.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/92\" class=\"nounderline abstract_t\">Salotra P, Sreenivas G, Beena KR, et al. Parasite detection in patients with post kala-azar dermal leishmaniasis in India: a comparison between molecular and immunological methods. J Clin Pathol 2003; 56:840.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/93\" class=\"nounderline abstract_t\">Burza S, Mahajan R, Sanz MG, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis 2014; 59:552.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/94\" class=\"nounderline abstract_t\">Pintado V, Mart&iacute;n-Rabad&aacute;n P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80:54.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/95\" class=\"nounderline abstract_t\">Alvar J, Ca&ntilde;avate C, Guti&eacute;rrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/96\" class=\"nounderline abstract_t\">Rosenthal E, Marty P, del Giudice P, et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000; 31:1093.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/97\" class=\"nounderline abstract_t\">Mota Sasaki Md, Matsumo Carvalho M, Schmitz Ferreira ML, Machado MP. Cutaneous Leishmaniasis Coinfection in AIDS Patients: Case Report and Literature Review. Braz J Infect Dis 1997; 1:142.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/98\" class=\"nounderline abstract_t\">Gonz&aacute;lez-Beato MJ, Moyano B, S&aacute;nchez C, et al. Kaposi's sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis. Br J Dermatol 2000; 143:1316.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/99\" class=\"nounderline abstract_t\">C&aacute;novas DL, Carbonell J, Torres J, et al. Laryngeal leishmaniasis as initial opportunistic disease in HIV infection. J Laryngol Otol 1994; 108:1089.</a></li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/100\" class=\"nounderline abstract_t\">Miralles ES, N&uacute;&ntilde;ez M, Hilara Y, et al. Mucocutaneous leishmaniasis and HIV. Dermatology 1994; 189:275.</a></li><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on July 10, 2017).</li><li><a href=\"https://www.uptodate.com/contents/visceral-leishmaniasis-clinical-manifestations-and-diagnosis/abstract/102\" class=\"nounderline abstract_t\">Medrano FJ, Ca&ntilde;avate C, Leal M, et al. The role of serology in the diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type-1. Am J Trop Med Hyg 1998; 59:155.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5732 Version 24.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H23\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOPHYSIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Asymptomatic infection</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Visceral leishmaniasis</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Viscerotropic disease</a></li><li><a href=\"#H24542225\" id=\"outline-link-H24542225\">- Renal impairment</a></li><li><a href=\"#H4576731\" id=\"outline-link-H4576731\">- Hemophagocytic lymphohistiocytosis</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Laboratory findings</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">DIAGNOSIS</a><ul><li><a href=\"#H1543162716\" id=\"outline-link-H1543162716\">Clinical approach</a></li><li><a href=\"#H1152948679\" id=\"outline-link-H1152948679\">Specimen collection</a></li><li><a href=\"#H2693328787\" id=\"outline-link-H2693328787\">Diagnostic tools</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">- Histopathology</a></li><li><a href=\"#H2396772608\" id=\"outline-link-H2396772608\">- Culture</a></li><li><a href=\"#H2524200777\" id=\"outline-link-H2524200777\">- Molecular techniques</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Serologic tests</a></li><li><a href=\"#H4188301534\" id=\"outline-link-H4188301534\">- Other assays</a></li></ul></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">SPECIAL CIRCUMSTANCES</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">Post-kala-azar dermal leishmaniasis</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">- Clinical manifestations</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">- Diagnosis</a></li></ul></li><li><a href=\"#H19\" id=\"outline-link-H19\">HIV-VL coinfection</a><ul><li><a href=\"#H20\" id=\"outline-link-H20\">- Clinical manifestations</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">- Diagnosis</a></li></ul></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5732|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/52344\" class=\"graphic graphic_picture\">- Leish bone marrow biopsy</a></li><li><a href=\"image.htm?imageKey=ID/80619\" class=\"graphic graphic_picture\">- PKDL macules</a></li><li><a href=\"image.htm?imageKey=ID/75252\" class=\"graphic graphic_picture\">- Papular PKDL</a></li><li><a href=\"image.htm?imageKey=ID/58427\" class=\"graphic graphic_picture\">- PKDL plaques</a></li></ul></li><li><div id=\"ID/5732|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/58861\" class=\"graphic graphic_table\">- Leishmaniasis species</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-hemophagocytic-lymphohistiocytosis\" class=\"medical medical_review\">Clinical features and diagnosis of hemophagocytic lymphohistiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">Clinical manifestations of malaria in nonpregnant adults and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-miliary-tuberculosis\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of miliary tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-non-hodgkin-lymphoma\" class=\"medical medical_review\">Clinical presentation and diagnosis of non-Hodgkin lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-treatment-of-disseminated-histoplasmosis-in-hiv-uninfected-patients\" class=\"medical medical_review\">Diagnosis and treatment of disseminated histoplasmosis in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">Diagnosis of malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-schistosomiasis\" class=\"medical medical_review\">Diagnosis of schistosomiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis\" class=\"medical medical_review\">Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathologic-features-and-diagnosis-of-classical-hodgkin-lymphoma\" class=\"medical medical_review\">Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extraintestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">Extraintestinal Entamoeba histolytica amebiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-and-clinical-manifestations-of-disseminated-histoplasmosis\" class=\"medical medical_review\">Pathogenesis and clinical manifestations of disseminated histoplasmosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-hemophagocytic-lymphohistiocytosis\" class=\"medical medical_review\">Treatment and prognosis of hemophagocytic lymphohistiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=visceral-leishmaniasis-epidemiology-and-control\" class=\"medical medical_review\">Visceral leishmaniasis: Epidemiology and control</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=visceral-leishmaniasis-treatment\" class=\"medical medical_review\">Visceral leishmaniasis: Treatment</a></li></ul></div></div>","javascript":null}